Scoring membranous HER2 staining as 1+, faint staining of ≥10% of the tumor cells; 2+, weak-to-moderate staining in ≥ 10% of the tumor cells; 3+, strong staining in 10% of the tumor cells. This evidence concerns the gene ERBB2 and neoplasm.